Blood D.E.S.E.R.T. Coalition’s Post

𝐂𝐚𝐬𝐞 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭: 𝐒𝐮𝐜𝐜𝐞𝐬𝐬𝐟𝐮𝐥 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐨𝐟 𝐈𝐧𝐭𝐮𝐬𝐬𝐮𝐬𝐜𝐞𝐩𝐭𝐢𝐨𝐧 𝐢𝐧 𝐚 𝟐-𝐘𝐞𝐚𝐫-𝐎𝐥𝐝 𝐰𝐢𝐭𝐡 𝐀𝐥𝐥𝐞𝐧𝐠𝐞𝐫𝐬 𝐀𝐝𝐯𝐚𝐧𝐜𝐞𝐝 𝐈𝐦𝐚𝐠𝐢𝐧𝐠 𝐒𝐲𝐬𝐭𝐞𝐦𝐬: 𝐄𝐜𝐨 𝐓𝐫𝐚𝐜𝐤-𝐃𝐑𝐅 A 2-year-old presented with suspected intussusception, a condition where part of the intestine telescopes into another segment, causing blockage and compromised blood flow. Using the 𝐄𝐜𝐨 𝐓𝐫𝐚𝐜𝐤-𝐃𝐑𝐅, the diagnosis and treatment were seamlessly integrated. An air contrast enema was performed, reducing the telescoping segment non-surgically. Real-time imaging confirmed success as gas passed through the small bowel loops, from the transverse colon to the cecum, ensuring complete recovery. With superior imaging and multi-functional capabilities, the 𝐄𝐂𝐎 𝐓𝐑𝐀𝐂𝐊 𝐃𝐑𝐅 𝐬𝐲𝐬𝐭𝐞𝐦 enables accurate diagnoses and minimally invasive treatments, reducing patient discomfort and enhancing clinical outcomes. At 𝐀𝐥𝐥𝐞𝐧𝐠𝐞𝐫𝐬, we are proud to empower healthcare professionals with innovative technologies that improve patient care. 𝐅𝐨𝐫 𝐦𝐨𝐫𝐞 𝐢𝐧𝐟𝐨𝐫𝐦𝐚𝐭𝐢𝐨𝐧: https://lnkd.in/gfhWZSjq

What are Photoplethysmography (PPG) sensors? PPG sensors are a valuable tool in the vascular laboratory, offering a non-invasive way to measure blood flow and perfusion in a variety of vascular beds. They have a wide range of clinical applications, including monitoring PAD, assessing the effectiveness of interventions, monitoring CLI, and monitoring blood flow in other patient populations. PPG sensors, being non-invasive, are valuable for monitoring blood flow in various vascular areas and internal organs. They find clinical applications in conditions like peripheral artery disease (PAD) and critical limb ischemia (CLI), aiding in interventions and treatment decisions. Specifically, in PAD, PPG sensors measure the ankle-brachial index (ABI) to indicate the severity of the disease. Read more: https://lnkd.in/ggdvzsPq #Healthcare #Medicine #VascularHealth #MedTech #Clinical

🚀Game-changer in the field of alpha-fetoprotein (AFP) detection. Alpha-fetoprotein, a protein primarily produced by the fetal liver and yolk sac tissues, plays a crucial role in various medical conditions. Elevated AFP levels at birth typically decline rapidly, making timely and accurate measurement crucial for effective patient management.🟢 Biotime AFP Rapid Quantitative Test rises to the challenge, delivering an unparalleled performance. Equipped with state-of-the-art technology, this test kit offers: ✅Accuracy ✅Fast Results ✅Ease of Use 🧑⚕️Elevate your diagnostic capabilities with the AFP Rapid Quantitative Test - the innovative solution that redefines the standard of AFP testing. Experience the power of precision and speed in your clinical practice. 🔗：https://lnkd.in/gfBv9cPA #AFP #TumorMarker #rapidtest #quantitative #alphafetoprotein #diagnostic #liver #healthcare #fia #innovative

This study explored the accuracy of CT-μFR, a non-invasive method to assess coronary lesions. The outcomes demonstrate that CT-μFR provided high diagnostic accuracy for identifying significant coronary stenosis, comparable to invasive methods, making it a promising tool in clinical practice. #EAPCI #coronarycomputedtomographyangiography https://ow.ly/mkep50TRN8x

For Healthcare Professionals & Healthcare Facilities! Don't miss the virtual "Capacity Building workshop on ABDM & PMJAY and a Brain Storming Session on Sickle Cell Anemia" on 19th June, Wednesday & interact with the industry experts from research institutes and government & private facilities. Stay tuned for more information on meeting Link & passcode! #AyushmanBharat #ABDM #PMJAY

📊NEW DATA: INFINITY-SWEDEHEART RCT 12-month outcomes comparing #DynamX®* with a contemporary DES in patients with acute coronary syndrome and complex lesion subsets after six months. ➡️ Landmark analysis (6-12 months) showed DynamX bioadaptor significantly reduces adverse events compared to DES, confirming unique mechanism of action after unlocking at 6 months ➡️ Clinical results in patients with ACS demonstrated 83% reduction (0.3% vs. 1.8%; (p<0.018)) in TLF rate ➡️ Clinical results in patients with lesions in the LAD vessels demonstrated 73% reduction (0.2% vs. 2.2%) in TLF rate ➡️ There were no TLF events in patients with small vessels (less than or equal to 2.75 mm) in the DynamX arm Learn more about the results: https://lnkd.in/etMwb9XZ INFINITY-SWEDEHEART data were published concurrently in The Lancet: https://lnkd.in/etYST6ap *CE marked. Not for sale in the U.S. #Cardiovascular #Medtech #Innovation #TCT2024 PMN 2032 REV A

Innovative approaches are transforming the treatment landscape for pulmonary embolism (PE) and deep vein thrombosis (DVT). From catheter-directed thrombolysis to AI-driven diagnostics and personalized medicine, these advancements drive better patient outcomes while aligning with trends in minimally invasive procedures. Market research highlights the rising adoption of pharmacomechanical thrombectomy and point-of-care diagnostics, reflecting the growing demand for precise and patient-centric solutions. As we look to the future, next-generation anticoagulants and telemedicine are set to improve VTE management further, making care more accessible and efficient. https://lnkd.in/dPkK9JBU #PulmonaryEmbolism #DeepVeinThrombosis #HealthcareInnovation #VTE #MarketResearch #MedicalTechnology #ThrombosisTreatment #PatientCare #AIinHealthcare #Telemedicine Pratik Lahiri

Do patients with atrial SMR experience clinical benefit when treated with #MitraClip? Dr. Mark Ricciardi presented an analysis of this SMR subgroup treated with MitraClip from the global EXPANDed studies at #HFSA2024, confirming the effectiveness of MitraClip for patients with atrial SMR. View the data: https://abbo.tt/HFSA24 Learn more about MitraClip: https://abbo.tt/MitraClip Important Safety Info: https://lnkd.in/dNT4vGyc #StructuralHeart #TEER

The YnY series Enhanced Electrochemiluminescence (EECL) Immunoassay Analyzers developed by Accucise Diagnostics have made remarkable progress in three aspects: - Patented electrically neutral luminous marker - NRC, - Optimized coupling chemistry of magnetic beads, - Advanced electrochemical mechanism. These innovations will enhance signal levels, reduce background noise, and improve sensitivity in EECL compared with traditional Electrochemiluminescence methods.

The YnY series Enhanced Electrochemiluminescence (EECL) Immunoassay Analyzers developed by Accucise Diagnostics have made remarkable progress in three aspects: - Patented electrically neutral luminous marker - NRC, - Optimized coupling chemistry of magnetic beads, - Advanced electrochemical mechanism. These innovations will enhance signal levels, reduce background noise, and improve sensitivity in EECL compared with traditional Electrochemiluminescence methods.